Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA Diabetes and Cancer Drugs Endorsed by EU Watchdog-Reuters


Friday, 16 Nov 2012 06:44am EST 

Reuters reported that Sanofi SA won the backing of European regulators for two new drugs against diabetes and cancer. New diabetes drug Lyxumia was recommended for treating type 2 diabetes and Zaltrap was endorsed for the treatment of advanced colorectal cancer, the European Medicines Agency (EMA) said. Recommendations from the EMA are normally endorsed by the European Commission within a couple of months. Lyxumia, which Sanofi SA licensed from Denmark's Zealand Pharma , is part of a new class of diabetes treatments called GLP-1 analogues which prompt the body to release insulin when a diabetic's blood sugar level climbs too high. 

Company Quote

84.27
 --
23 Oct 2014